Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial ...
Neuronetics Provides Business Update and Issues 2025 Guidance
Preliminary unaudited fourth quarter and full year revenue 2024 was $22.1 and $74.5, respectivelyClosed acquisition of Greenbrook TMS effective as of December 9, 2024Expects full year 2025 pro forma ...